The Focal Segmental Glomerulosclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Focal Segmental Glomerulosclerosis: An Overview
Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed.
FSGS may be found either in primary or secondary forms. Primary FSGS sometimes has no identifiable cause or known etiology and is linked to genetic mutations in podocyte-specific proteins, while secondary FSGS might include familial/genetic forms, virus-associated forms, drug-induced forms, and forms mediated by the adaptive structural-functional response.
Focal Segmental Glomerulosclerosis Market Key Facts
-
In 2017, there were 45,800+ prevalent cases of FSGS in males and 34,700+ cases in females and as per analyst assessments, the overall cases of FSGS in both the genders are subjected to increase in the coming years in 7MM.
-
Among the European 5 countries, Germany had the highest prevalent population of FSGS with 21,500+ cases, followed by France. On the other hand, Spain had the lowest prevalent population of Focal Segmental Glomerulosclerosis.
-
Among the 7MM, The most prevalent causes of FSGS were recorded in the United States.
Focal Segmental Glomerulosclerosis Market
Focal Segmental Glomerulosclerosis (FSGS) market size is anticipated to increase during the study period owing to the increasing prevalent population of FSGS in the 7MM. The launch of the emerging therapies will also fuel market growth. At present few companies are performing clinical trials to develop cell therapies and receptor modulators for the treatment of FSGS
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Focal Segmental Glomerulosclerosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Focal Segmental Glomerulosclerosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Focal Segmental Glomerulosclerosis Epidemiology
The epidemiology section covers insights into the historical and current Focal Segmental Glomerulosclerosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched in the market during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in various stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market
Focal Segmental Glomerulosclerosis Therapeutics Analysis
The available therapeutics treatment options in the Focal Segmental Glomerulosclerosis (FSGS) landscape aim to reduce complications and protect from further kidney damage. Few companies are performing clinical trials to develop cell therapies and receptor modulators for the treatment of FSGS.
Some of the key companies in the Focal Segmental Glomerulosclerosis (FSGS) Market include:
-
Retrophin
-
Aurinia Pharmaceuticals
-
Dimerix
-
Complexa
-
Bristol-Myers Squibb
-
Astellas Pharma
-
Pfizer
And many others.
Focal Segmental Glomerulosclerosis (FSGS) Therapies covered in the report include:
-
Sparsentan
-
Voclosporin
-
DMX-200
-
CXA-10
-
Abatacept
-
Bleselumab
-
PF-06730512
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Focal Segmental Glomerulosclerosis Competitive Intelligence Analysis
4. Focal Segmental Glomerulosclerosis Market Overview at a Glance
5. Focal Segmental Glomerulosclerosis Disease Background and Overview
6. Focal Segmental Glomerulosclerosis Patient Journey
7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8. Focal Segmental Glomerulosclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Focal Segmental Glomerulosclerosis Unmet Needs
10. Key Endpoints of Focal Segmental Glomerulosclerosis Treatment
11. Focal Segmental Glomerulosclerosis Marketed Products
12. Focal Segmental Glomerulosclerosis Emerging Therapies
13. Focal Segmental Glomerulosclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Focal Segmental Glomerulosclerosis Market Outlook (7 major markets)
16. Focal Segmental Glomerulosclerosis Access and Reimbursement Overview
17. KOL Views on the Focal Segmental Glomerulosclerosis Market.
18. Focal Segmental Glomerulosclerosis Market Drivers
19. Focal Segmental Glomerulosclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
“West Nile Encephalitis Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the West Nile Encephalitis market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/